American Association for Cancer Research
15417786mcr110559-sup-fig4.pdf (686.22 kB)

Supplementary Figure 4 from The p38 MAPK–MK2 Axis Regulates E2F1 and FOXM1 Expression after Epirubicin Treatment

Download (686.22 kB)
journal contribution
posted on 2023-04-03, 17:47 authored by Natalia de Olano, Chuay-Yeng Koo, Lara J. Monteiro, Paola H. Pinto, Ana R. Gomes, Rosa Aligue, Eric W.-F. Lam

PDF file, 686K, Effects of p38α knockdown on P-E2F1, E2F1 and FOXM1 induction in response to epirubicin in MCF-7 and MCF-7EpiR cells.



E2F1 is responsible for the regulation of FOXM1 expression, which plays a key role in epirubicin resistance. Here, we examined the role and regulation of E2F1 in response to epirubicin in cancer cells. We first showed that E2F1 plays a key role in promoting FOXM1 expression, cell survival, and epirubicin resistance as its depletion by siRNA attenuated FOXM1 induction and cell viability in response to epirubicin. We also found that the p38–MAPK activity mirrors the expression patterns of E2F1 and FOXM1 in both epirubicin-sensitive and -resistant MCF-7 breast cancer cells, suggesting that p38 has a role in regulating E2F1 expression and epirubicin resistance. Consistently, studies using pharmacologic inhibitors, siRNA knockdown, and knockout mouse embryonic fibroblasts (MEF) revealed that p38 mediates the E2F1 induction by epirubicin and that the induction of E2F1 by p38 is, in turn, mediated through its downstream kinase MK2 [mitogen-activated protein kinase (MAPK)-activated protein kinase 2; MAPKAPK2]. In agreement, in vitro phosphorylation assays showed that MK2 can directly phosphorylate E2F1 at Ser-364. Transfection assays also showed that E2F1 phosphorylation at Ser-364 participates in its induction by epirubicin but also suggests that other phosphorylation events are also involved. In addition, the p38–MK2 axis can also limit c-jun-NH2-kinase (JNK) induction by epirubicin and, notably, JNK represses FOXM1 expression. Collectively, these findings underscore the importance of p38–MK2 signaling in the control of E2F1 and FOXM1 expression as well as epirubicin sensitivity. Mol Cancer Res; 10(9); 1189–202. ©2012 AACR.